

**IN THE SPECIFICATION:**

Page 2, Line 11, change "if" to -in—

Page 2, Line 21, change "HMB phosphatidylserine" to —HMB, phosphatidylserine—

Page 11, Line 22, change "(nucleocapsid inhibitors) While" to -(nucleocapsid inhibitors).

While—

Page 11, Line 14, change "BCH-10652" to BCH 10652 (2'-deoxy-3'-oxa-4'-thiocytidine)—

Page 11, Line 14, change "FTC-TBD" to FTC (the 5'-fluoro congener of 3TC)—

Page 11, Line 15, change "MKC-482/TBD" to MKC-442 (a new non-nucleoside reverse

transcriptase inhibitor)

Page 11, Line 16, change "PMPA/bis-poc PMPA" to Bis-POC-PMPA (the deoxyadenosine

monophosphate analogue of 9-[2-(R)-(phosphonomethoxy)propyl]adenine)

Page 19, Line 21, change "suspention" to -suspension—

Page 21, table, change "ritonair" to -ritonavir—

Page 22, table, change "ritonair" to -ritonavir—

**IN THE CLAIMS:**

Kindly rewrite Claims 1, 2, 6, 7, 10, 11 and 15 as follows: